Dr. Pawel Mroz is a member of the department's Division of Molecular Pathology and Genomics. He is board certified in anatomic and clinical pathology with expertise in hematopathology and molecular genetic pathology and he will provide primary service in the Molecular Diagnostic Laboratory as well as hematopathology.Dr Mroz's early research interests included translational applications of photodynamic therapy for cancer treatment as well as investigating the role of tumor associated antigens and T regulatory cells in anti-tumor immune response. Currently his research interests are focused on two areas: Droplet digital polymerase chain reaction (ddPCR) and next-generation sequencing (NGS) technologies. Droplet digital PCR (ddPCR) is a novel diagnostic platform that provides absolute quantification of amplification targets by partitioning and separately analyzing each PCR reaction. ddPCR is a refinement of conventional and quantitative PCR as it demonstrates robust performance characteristics and may offer improved detection of low-level disease. ddPCR has the potential to become an especially valuable diagnostic and prognostic tool in hematologic malignancies like acute lymphoblastic leukemia or acute myeloid leukemia as it may allow for earlier detection of relapse or persistence of disease.Next-generation DNA sequencing is beginning to be applied in the initial diagnosis and classification of a growing number of malignancies. Dr Mroz has experience in the clinical application of NGS but wants to focus on developing new translational applications for NGS in the research setting that over time can be brought to the clinic. The technical dimension of NGS is fairly well understood but its use in characterizing hematologic malignancies is at an early stage of development. Dr Mroz sees opportunities for adding new NGS applications for better characterization and classification of hematologic malignancies.
Salloum RG, Bishop JR, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Tuteja S.Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implement Sci Commun. 2022 May 14;3(1):52. doi: 10.1186/s43058-022-00300-7.
Mroz P, Michel S, Allen JD, Meyer T, McGonagle EJ, Carpentier R, Vecchia A, Schlichte A, Bishop JR, Dunnenberger HM, Yohe S, Thyagarajan B, Jacobson PA, Johnson SG. Development and implementation of in-house pharmacogenomic testing program at a major academic health system. Front Genet. 2021 Oct 20;12:712602. doi: 10.3389/fgene.2021.712602.
Oltvai ZN, Harley SE, Koes D, Michel S, Warlick ED, Nelson AC, Yohe S, Mroz P. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. Cold Spring Harb Mol Case Stud. 2021 Apr 8;7(2):a006007. doi: 10.1101/mcs.a006007.
Ryan J. Martinez, Qing Kang, Davis Nennig, Nathanael G. Bailey, Noah A. Brown, Bryan L. Betz, Muneesh Tewari, Bharat Thyagarajan, Veronika Bachanova, Pawel Mroz. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.Arch Pathol Lab Med2021; doi:https://doi.org/10.5858/arpa.2020-0454-OA
Fujiyoshi K, Bruford EA, Mroz P, Sims CL, O'Leary TJ, Lo AWI, Chen N, Patel NR, Patel KP, Seliger B, Song M, Monzon FA, Carter AB, Gulley ML, Mockus SM, Phung TL, Feilotter H, Williams HE, Ogino S. Opinion: Standardizing gene product nomenclature-a call to action. Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):e2025207118. doi 10.1073/pnas.2025207118.
Fellowships, Residencies, and Visiting Engagements
Licensures and Certifications
AddressRm D222 Mayo
420 Delaware St SE
Minneapolis, MN 55455